KRAS and neoplasm: A trend towards more frequent KRAS mutations was observed for tumors of the sinonasal cavity (5.67%; 95% CI, 1.33-12.74) as compared to tumors of the salivary glands (0.98%; 95% CI, 0.33-1.96), oral cavity (0.7%; 95% CI, 0.17-1.59), oropharynx (1.49%; 95% CI, 0.6-2.77), nasopharynx (0.83%; 95% CI, 0.29-1.63), larynx (1.43%; 95% CI, 0.34-3.25), or hypopharynx (0.84%; 95% CI, 0-3.18).